Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 6—June 2011


Outcome Predictors in Treatment of Yaws

Oriol MitjàComments to Author , Russell Hays, Anthony Ipai, David Gubaila, Francis Lelngei, Martin Kirara, Raymond Paru, and Quique Bassat
Author affiliations: Author affiliations: Lihir Medical Centre, Lihir Island, Papua New Guinea (O. Mitjà, R. Hays, A. Ipai, D. Gubaila, F. Lelngei, M. Kirara, R. Paru); Barcelona Centre for International Health Research, Barcelona, Spain (Q. Bassat)

Main Article

Table 1

Demographic data, clinical signs/symptoms, laboratory results, and outcome after treatment of yaws in 138 case-patients, Papua New Guinea, January–September, 2009*

Characteristic Total no. (%) patients, N = 138
Mean age, y (SD) 9.6 (4.4)
Male sex
81 (58.7)
VDRL titer
16 54 (39.1)
32 33 (23.9)
64 42 (30.4)
9 (6.5)
Primary skin lesion 81 (58.7)
Secondary stage
63 (45.7)†
Family history
36 (26.1)
Treatment with IM penicillin G benzathine 138 (100.0)
Clinical healing 132 (95.7)
Concurrent disease 7 (5.1)‡
Seroconversion 63 (45.7)
Serologically defined treatment failure 24 (17.4)

*VDRL, Venereal Disease Research Laboratory; IM, intramuscular.
†Includes 7 cases of early yaws osteoperiostitis, among whom were 3 patients with dactylilitis.
‡Includes 3 cases of Plasmodium falciparum malaria, 1 case of P. vivax malaria, 1 case of acute diarrhea diagnosed at the 12-month follow-up visit, and 2 case-patients with a chronic underlying disease (1 case of congenital heart disease and 1 case of chronic asthma).

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO